Study of combined CO2 laser therapy with exosome injection in the treatment of vitiligo

Safety and efficacy of combined CO2 laser therapy with Wharton's jelly mesenchymal stem cell-derived exosomes injection in the treatment of vitiligo compared to CO2 laser and steroid injection: Phase 1 clinical trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200127046282N64

Enrollment

Registered

2025-12-24

Start date

2026-01-05

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: Patients receive exosomes in the form of injections at a concentration of 1 microgram per milliliter after CO2 laser (10,600 nm CO2 laser device) three times with a

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Having no treatment within past 6 months No pregnancy or breast-feeding Have a diagnosis of vitiligo with depigmented patch more than 5 cm despite receiving at least 3 months active treatment No infection at recipient site No history of keloid and or koebner phenomenon No history of active hepatitis the B, C, or AIDS No active uncontrolled chronic systemic disease

Exclusion criteria

Exclusion criteria: Vitiligo patients with active or progressive disease within last 12 months.

Design outcomes

Primary

Measure	Time frame
Repigmentation rate. Timepoint: Before, 1, 3 and 6 months after treatment. Method of measurement: The amount of melanin in the treated areas compared to before treatment using a maxameter device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Skin and Stem cell Research Center of Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026